The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Modeling the expansion of virtual screening libraries
Open accessPublished version of a preprint
Abstract
Recently, 'tangible' virtual libraries have made billions of molecules readily available. Prioritizing these molecules for synthesis and testing demands computational approaches, such as docking. Their success may depend on library diversity, their similarity to bio-like molecules and how receptor fit and artifacts change with library size. We compared a library of 3 million 'in-stock' molecules with billion-plus tangible libraries. The bias toward bio-like molecules in the tangible library decreases 19,000-fold versus those 'in-stock'. Similarly, thousands of high-ranking molecules, including experimental actives, from five ultra-large-library docking campaigns are also dissimilar to bio-like molecules. Meanwhile, better-fitting molecules are found as the library grows, with the score improving log-linearly with library size. Finally, as library size increases, so too do rare molecules that rank artifactually well. Although the nature of these artifacts changes from target to target, the expectation of their occurrence does not, and simple strategies can minimize their impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“GANs (95), inspired by game theory and deep learning, have found applications in chemistry, such as the first deep learning GAN used in anti-cancer compound design (96).”
From Artificial Intelligence for Drug Discovery: Are We There Yet? (2024) · cites this paper as [95]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Angewandte Chemie International Edition
Vazdar, K., Kunetskiy, R. A., Saame, J., Kaupmees, K., Leito, I., & Jahn, U. (2006) · Angewandte Chemie International Edition · doi:10.1002/(issn)1521-3773 · Cited by 5,242
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,579
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,501
ChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C. A., Lynch, M., Lowinger, T., Dumas, J., Smith, R., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature reviews. Drug discovery · doi:10.1038/nrd2130 · Cited by 1,651
Molecular signatures of G-protein-coupled receptors
Venkatakrishnan, A., Deupí, X., Lebon, G., Tate, C. G., Schertler, G. F. X., & Babu, M. M. (2013) · Nature · doi:10.1038/nature11896 · Cited by 1,534
JOURNAL OF CHEMICAL INFORMATION AND MODELING
(2005) · Chemical & Engineering News · doi:10.1021/cen-v083n019.p031 · Cited by 1,534
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Research works printed but not linked: 1
- Lipinski, C. A. Physicochemical properties and the discovery of orally active drugs: technical and people issues. In Molecular Informatics: Confronting Complexity, Proceedings of the Beilstein-Institut Workshop (Frankfurt, 2003).
Cited by
Sorted by citations
Computational approaches streamlining drug discovery
Sadybekov, A., & Katritch, V. (2023) · Nature · doi:10.1038/s41586-023-05905-z · Cited by 1,424
Artificial intelligence in drug development
Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G. L., Li, X., Wu, J. C., & Yang, S. (2025) · Nature Medicine · doi:10.1038/s41591-024-03434-4 · Cited by 585
The Art and Science of Molecular Docking
Paggi, J. M., Pandit, A., & Dror, R. O. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030222-120000 · Cited by 546
ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries
Swanson, K., Walther, P., Leitz, J., Mukherjee, S., Wu, J. C., Shivnaraine, R. V., & Zou, J. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae416 · Cited by 451
ZINC-22─A Free Multi-Billion-Scale Database of Tangible Compounds for Ligand Discovery
Tingle, B. I., Tang, K. G., Castanon, M., Gutierrez, J. J., Khurelbaatar, M., Dandarchuluun, C., Moroz, Y. S., & Irwin, J. J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01253 · Cited by 314
Self-citation
Metadata
- Authors
- Lyu, J., Irwin, J. J., & Shoichet, B. K.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Irwin, John J.
- Shoichet, Brian K.
- Venue
- Nature Chemical Biology
- Published
- 2023-01-16
- Volume
- 19
- Issue
- 6
- Pages
- 712-718
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC10243288
- OpenAlex
- W4316507591
- Cited by
- 193
- References
- 53
- Citations by year
- 2026: 49 · 2025: 57 · 2024: 55 · 2023: 31
- FWCI
- 27.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Chemical Biology (publishedVersion)
- ChemRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM133836, R35GM122481)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Keywords
- library size, molecular diversity, molecular similarity, protein-ligand docking
- MeSH terms
- Libraries, Digital, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
